Clinical-epidemiological analysis of patients with elevated lipoprotein A in a third level hospital

Clin Investig Arterioscler. 2024 May-Jun;36(3):118-125. doi: 10.1016/j.arteri.2023.12.001. Epub 2023 Dec 30.
[Article in English, Spanish]

Abstract

Objective: The objective of the study is to describe the clinical and epidemiological characteristics of our patients with elevated Lp(a).

Materials and methods: A descriptive cross-sectional study was conducted on 316 patients with elevated Lp(a) (>125 nmol/L) in a random sample between January and August 2022. We measured epidemiological, anthropometric, clinical and laboratory variables (lipid metabolism parameters, carbohydrates and hormones).

Results: Mean age of our sample subject's was 59 ± 15 years with 56% males. The average BMI was 27.6 kg/m2 (71% with elevated BMI). Elevated waist circumference was observed in 54.1% of men and 77.8% of women. 48% had hypertension, 30.7% had diabetes mellitus and 91.5% dyslipidemia. Only 39.7% of the patients had never smoked. The mean values of total cholesterol were 158 ± 45 mg/dl, LDL was 81 ± 39 mg/dl, HDL was 53 ± 17 mg/dl, Triglycerides were 127 ± 61 mg/dl, and Lp(a) was 260 ± 129 nmol/L. Regarding lipid lowering treatment, 89% were on statins, 68.6% on ezetimibe, and 13.7% on PCSK9 inhibitors. 177 patients (57,7%) had established cardiovascular disease (CVD), 16.3% had polyvascular disease, 11.7% had subclinical CVD, and 30.6% had no known CVD. Among patients with established CVD, 174 (98.3%) were on lipid-lowering treatment (97.2% on statins) and 86.4% were on antiplatelet therapy. The mean age of cardiovascular events was 55 ± 12 years in males and 60 ± 11 years in females. 65,1% of female and 56,2% of male patients suffered an early cardiovascular event.

Conclusions: Patients with elevated Lp(a) are at very high cardiovascular risk, particularly for early cardiovascular disease.

Keywords: Cardiovascular risk factors; Cardiovascular risk stratification; Dislipemia; Dyslipidemia; Early cardiovascular disease; Enfermedad cardiovascular precoz; Estratificación de riesgo cardiovascular; Factores de riesgo cardiovascular; Lipoprotein(a); Lipoproteína(a).

MeSH terms

  • Adult
  • Aged
  • Body Mass Index
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology
  • Cross-Sectional Studies
  • Diabetes Mellitus / epidemiology
  • Dyslipidemias* / epidemiology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypertension / epidemiology
  • Lipoprotein(a)* / blood
  • Male
  • Middle Aged
  • Risk Factors
  • Tertiary Care Centers
  • Waist Circumference

Substances

  • Lipoprotein(a)
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors